Ernexa Therapeutics Inc.

NasdaqCM:ERNA Stock Report

Market Cap: US$10.4m

Ernexa Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ERNA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Apr 25BuyUS$394,174Charles CheringtonIndividual3,768,397US$0.10

Insider Trading Volume

Insider Buying: ERNA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ERNA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies00%
Institutions2,273,2064.35%
VC/PE Firms6,211,52011.9%
General Public8,352,41216%
Individual Insiders35,407,79167.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 865.7%.

Top Shareholders

Top 25 shareholders own 84.01% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
39%
Charles Cherington
20,401,602US$4.1m22.6%no data
11.9%
Freebird Partners LP
6,211,520US$1.2m20.9%99.99%
11.2%
John Halpern
5,856,830US$1.2m16.6%no data
9.55%
George Denny
4,990,641US$996.1k991%no data
6.23%
David Laughlin
3,255,421US$649.8k21.5%no data
1.91%
Purchase Capital LLC
1,000,001US$199.6k0%no data
1.55%
Nicholas Singer
810,000US$161.7k0%no data
0.51%
Pacific Premier Bancorp Inc, Asset Management Arm
266,214US$53.1k0%no data
0.5%
Corient Private Wealth LLC
262,862US$52.5k0%no data
0.49%
Geode Capital Management, LLC
257,310US$51.4k1,160%no data
0.18%
Cypress Point Wealth Management, LLC
94,375US$18.8k0%0.01%
0.18%
Shameek Konar
92,112US$18.4k0%no data
0.15%
Sippican Capital Advisors LLC
80,000US$16.0k60%0.01%
0.09%
Naviter Wealth LLC
47,271US$9.4k0%no data
0.086%
Millennium Management LLC
45,046US$9.0k0%no data
0.079%
XTX Holdings Limited, Asset Management Arm
41,382US$8.3k-28.8%no data
0.06%
Susquehanna International Group, LLP, Asset Management Arm
31,167US$6.2k0%no data
0.057%
Two Sigma Securities, LLC, Asset Management Arm
29,736US$5.9k-9.51%no data
0.05%
The Vanguard Group, Inc.
26,099US$5.2k0%no data
0.041%
Point72 Asset Management, L.P.
21,365US$4.3k0%no data
0.032%
UBS Asset Management AG
16,857US$3.4k-79.8%no data
0.028%
Avidian Wealth Enterprises, LLC
14,798US$3.0k0%no data
0.025%
Goldman Sachs Group, Investment Banking and Securities Investments
12,813US$2.6k0%no data
0.024%
BlackRock, Inc.
12,300US$2.5k-17.6%no data
0.021%
One8zero8, LLC
10,873US$2.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 14:46
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ernexa Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Jason McCarthyMaxim Group